Antitrust issues in the U.S. and Canada done,
There's nothing left to do.
And to that I say: "Boo-hoo."
(Don't worry, I'm done rhyming.)
The ticker will be gone -- oh, WYE, WYE, WYE? Not even a hyphenated name will remain. What would founders John and Frank Wyeth think?
Of course, it hadn't been Wyeth for very long -- only since 2002. Before that it was American Home Products. A catchy name, for sure. But not the company Wyeth had become.
Turning into a Johnson & Johnson
Or maybe it was Fen-phen. Merck's
Whatever the reason, Pfizer liked what it saw: a nice vaccine in Prevnar and a biologic with Enbrel. Those should be much harder to copy than Lipitor, that's for sure.
Ironically, it was a smaller acquisition of American Cyanamid that jump-started vaccines. Enbrel came through an Immunex partnership, before Amgen
No matter, it's done.
On to cost-saving-synergy lists that can't fail.
It's the pipeline I'm worried about;
R&D doesn't scale.
(Sorry, couldn't help myself.)
What are your expectations of the new Pfizer? Would you buy shares today (or tomorrow)? Let us know in the comments below.